Home
ONCY
ONCY News

Latest Oncolytics Biotech Inc. (ONCY) News on April 2, 2025

MT Newswires

23 days ago

RBC on Oncolytics's Phase 2 Breast Cancer Trial

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

GuruFocus.com

25 days ago

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

MT Newswires

a month ago

Oncolytics Q4 Net Loss Doubles, Provides Pelareorep Update

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

PR Newswire

a month ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a month ago

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

PR Newswire

a month ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

CNW Group

a month ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

MT Newswires

a month ago

Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

PR Newswire

a month ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

MT Newswires

a month ago

Oncolytics Biotech Gets Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

PR Newswire

2 months ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

MT Newswires

2 months ago

Oncolytics Biotech CEO to Step Down Following Medical Leave of Absence

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

CNW Group

2 months ago

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX

Simply Wall St.

2 months ago

Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX

Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

2 months ago

Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?

MT Newswires

2 months ago

Oncolytics Biotech to Present New Efficacy and Safety Data at ASCO Symposium

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

CNW Group

2 months ago

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial

Clinical Trials Arena

3 months ago

German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial

MT Newswires

3 months ago

Oncolytics Biotech Says German Regulatory Approval Received for Full Patient Enrollment in Pancreatic Cancer Study

MT Newswires

3 months ago

Oncolytics Biotech Up 6.5% in U.S. Pre-Market as Germany Approves Continuing GOBLET Enrollment

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

PR Newswire

3 months ago

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?

Simply Wall St.

3 months ago

Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

PR Newswire

3 months ago

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data

MT Newswires

3 months ago

Oncolytics Biotech to Present "Promising" Pelareorep Data at ASCO GI Symposium

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

PR Newswire

3 months ago

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

MT Newswires

4 months ago

Oncolytics Biotech Competes Safety Phase Enrollment for GOBLET Trial's Pancreatic Cancer Cohort

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

CNW Group

4 months ago

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

5 months ago

Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

MT Newswires

5 months ago

Oncolytics Biotech Q3 Loss Narrows

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

PR Newswire

5 months ago

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

PR Newswire

5 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

CNW Group

5 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights

ONCY Stock Up on Regulatory Update From Breast Cancer Program

Zacks

6 months ago

ONCY Stock Up on Regulatory Update From Breast Cancer Program

Oncolytics targets accelerated approval for oncolytic virus therapy

Pharmaceutical Technology

6 months ago

Oncolytics targets accelerated approval for oncolytic virus therapy

MT Newswires

6 months ago

Oncolytics Biotech Provides Clinical Updates

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

CNW Group

6 months ago

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

MT Newswires

6 months ago

Oncolytics Biotech Reports "Favorable" Results for BRACELET-1 Breast Cancer Study

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

PR Newswire

6 months ago

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

PR Newswire

7 months ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

CNW Group

7 months ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

Sernova Corp. Announces Appointment of New Chief Executive Officer

GlobeNewswire

8 months ago

Sernova Corp. Announces Appointment of New Chief Executive Officer

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

PR Newswire

8 months ago

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference

MT Newswires

8 months ago

Oncolytics Biotech Reports Q2 Loss of $7.5 Million

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

CNW Group

8 months ago

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Simply Wall St.

8 months ago

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

CNW Group

8 months ago

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights

MT Newswires

9 months ago

Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

CNW Group

9 months ago

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

MT Newswires

9 months ago

Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence

MT Newswires

9 months ago

Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

PR Newswire

9 months ago

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

Oncolytics doses first subject in pancreatic cancer trial

Clinical Trials Arena

9 months ago

Oncolytics doses first subject in pancreatic cancer trial

MT Newswires

9 months ago

Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

PR Newswire

9 months ago

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks

10 months ago

Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

MT Newswires

10 months ago

Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

CNW Group

10 months ago

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

PR Newswire

a year ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

MT Newswires

a year ago

Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

CNW Group

a year ago

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript

MT Newswires

a year ago

Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

PR Newswire

a year ago

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

MT Newswires

a year ago

Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

PR Newswire

a year ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

CNW Group

a year ago

Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

PR Newswire

a year ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

CNW Group

a year ago

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

CNW Group

a year ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire

a year ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

PR Newswire

a year ago

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

PR Newswire

a year ago

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

CNW Group

a year ago

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

CNW Group

a year ago

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

CNW Group

a year ago

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Newsfile

a year ago

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

CNW Group

a year ago

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

CNW Group

a year ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

CNW Group

a year ago

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

PR Newswire

a year ago

Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Newsfile

a year ago

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

CNW Group

a year ago

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

P3 Health Partners to Participate in The 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Business Wire

a year ago

P3 Health Partners to Participate in The 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

ISG to Publish Reports on Google Cloud Ecosystem

Business Wire

a year ago

ISG to Publish Reports on Google Cloud Ecosystem

Community West Bancshares Reports Full Year Earnings Amid Merger Developments

GuruFocus.com

a year ago

Community West Bancshares Reports Full Year Earnings Amid Merger Developments

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

InvestorPlace

a year ago

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

Here's Why DHI Group (NYSE:DHX) Has Caught The Eye Of Investors

Simply Wall St.

a year ago

Here's Why DHI Group (NYSE:DHX) Has Caught The Eye Of Investors

BCB Bancorp, Inc. (NASDAQ:BCBP) most popular amongst retail investors who own 51% of the shares, institutions hold 36%

Simply Wall St.

a year ago

BCB Bancorp, Inc. (NASDAQ:BCBP) most popular amongst retail investors who own 51% of the shares, institutions hold 36%

GuruFocus.com

a year ago

BCB Bancorp Inc (BCBP) Reports Decline in Q4 Earnings and Announces Dividend

Compared to Estimates, BCB Bancorp (BCBP) Q4 Earnings: A Look at Key Metrics

Zacks

a year ago

Compared to Estimates, BCB Bancorp (BCBP) Q4 Earnings: A Look at Key Metrics

Strength Seen in Flux Power Holdings, Inc. (FLUX): Can Its 8.4% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Flux Power Holdings, Inc. (FLUX): Can Its 8.4% Jump Turn into More Strength?

Provident Financial Holdings To Host Earnings Release Conference Call

GlobeNewswire

a year ago

Provident Financial Holdings To Host Earnings Release Conference Call

Hyliion to Participate in POWERGEN International Conference

Business Wire

a year ago

Hyliion to Participate in POWERGEN International Conference

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

TAT Technologies signs another 5-year contract with an international air carrier for APU MRO services with estimated total revenues of $10 million

PR Newswire

a year ago

TAT Technologies signs another 5-year contract with an international air carrier for APU MRO services with estimated total revenues of $10 million

China Automotive Systems (NASDAQ:CAAS) Is Doing The Right Things To Multiply Its Share Price

Simply Wall St.

a year ago

China Automotive Systems (NASDAQ:CAAS) Is Doing The Right Things To Multiply Its Share Price

C&F Financial (NASDAQ:CFFI) shareholders have earned a 19% CAGR over the last three years

Simply Wall St.

a year ago

C&F Financial (NASDAQ:CFFI) shareholders have earned a 19% CAGR over the last three years

Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024

PR Newswire

a year ago

Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024

Share on Social Networks: